Compass TherapeuticsCMPX +0.86%23 EV-to-EBITDA is -3.21 as of Jul. 09, 2026. GuruFocus rates CMPX with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 390 Biotechnology companies, Compass Therapeutics ranks worse than 256410% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Compass Therapeutics's enterprise value is $236.51 Mil.
Compass Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-73.70 Mil. Therefore, Compass Therapeutics's EV-to-EBITDA for today is -3.21.
The historical rank and industry rank for Compass Therapeutics's EV-to-EBITDA or its related term are showing as below:
CMPX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -13.21 Med: -3.99 Max: 0.66
Current: -3.21
During the past 8 years, the highest EV-to-EBITDA of Compass Therapeutics was 0.66. The lowest was -13.21. And the median was -3.99.
CMPX's EV-to-EBITDA is ranked worse than 100% of 390
companies
in the Biotechnology industry
Industry Median: 13.095
vs CMPX: -3.21
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Compass Therapeutics's PE Ratio (TTM) for today is calculated as:
Compass Therapeutics's share price for today is $2.34.
Compass Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.410.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Compass Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Compass Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Compass Therapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Compass Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Compass Therapeutics's EV-to-EBITDA falls into.
Compass Therapeutics's current Enterprise Value is $236.51 Mil.
Compass Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-73.70 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Compass Therapeutics (CMPX) has a EV-to-EBITDA of -3.21 as of Jul. 09, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Compass Therapeutics. According to the industry distribution chart, Compass Therapeutics ranks #999999 out of 390 companies in the Biotechnology industry.
Is Compass Therapeutics' EV-to-EBITDA too high?
Compass Therapeutics' current EV-to-EBITDA is -3.21. Based on the distribution chart, Compass Therapeutics ranks #999999 out of 390 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Compass Therapeutics has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Compass Therapeutics' EV-to-EBITDA compare to XFOR and LRMR?
According to the Biotechnology industry distribution chart, Compass Therapeutics ranks #999999 out of 390 companies for EV-to-EBITDA. This places Compass Therapeutics in the lower half of its industry. The industry median EV-to-EBITDA is 13.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.10, based on 390 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Compass Therapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 13.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Compass Therapeutics's current EV-to-EBITDA is -3.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compass Therapeutics stock overvalued right now?
Compass Therapeutics (CMPX) has a current EV-to-EBITDA of -3.21. The current EV-to-EBITDA is -3.21. Compass Therapeutics' overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Compass Therapeutics (CMPX), the current EV-to-EBITDA is -3.21 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
23GF Score
Get the complete analysis for CMPX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMPX has been successfully added to your 
